<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135785</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-18185-2</org_study_id>
    <secondary_id>P50-DA018185-2</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00135785</nct_id>
  </id_info>
  <brief_title>Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Evaluation of Bupropion vs Placebo for the Treatment of Methamphetamine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methamphetamine is an addictive stimulant drug that strongly activates certain parts of the&#xD;
      brain. The purpose of this study is to determine the effectiveness of bupropion in&#xD;
      combination with behavioral therapy for the treatment of methamphetamine addiction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methamphetamine is a drug that causes excess amounts of the neurotransmitters dopamine and&#xD;
      norepinephrine to be released into the brain. This overload produces unusual alertness and&#xD;
      feelings of elation. When the body undergoes methamphetamine withdrawal, it experiences a&#xD;
      reduction in dopamine and norepinephrine. Bupropion is an antidepressant used for the&#xD;
      treatment of depression and smoking cessation. Because it functions by increasing the release&#xD;
      of dopamine and norepinephrine in the brain, bupropion is likely to decrease the negative&#xD;
      effects of methamphetamine withdrawal. The purpose of this study is to evaluate the efficacy&#xD;
      of bupropion combined with contingency management (CM) and cognitive behavioral counseling&#xD;
      (CBT) as a means of treating methamphetamine dependence.&#xD;
&#xD;
      An initial 2-week screening process will involve participants providing urine samples and&#xD;
      completing physical and psychological assessments. If deemed eligible for the remainder of&#xD;
      this double-blind study, participants will be randomly assigned to receive either bupropion&#xD;
      or placebo over the course of 12 weeks. Participants in both the bupropion and placebo groups&#xD;
      will receive contingency management and cognitive behavioral counseling. Participants will&#xD;
      report to one of two clinical research sites three times per week. At each visit,&#xD;
      participants will be examined by the study staff, provide a urine sample, and receive&#xD;
      individual cognitive behavioral counseling sessions. At the end of 12 weeks, treatment will&#xD;
      be stopped. Participants will return to the study site 30 days later for evaluation and to be&#xD;
      assessed for any possible lingering side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Addiction severity, Week 16</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug use, Week 16</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Methamphetamine</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupropion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets DSM-IV criteria for methamphetamine dependence&#xD;
&#xD;
          -  Females must use an effective method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of or current medical condition that might interfere with safe participation,&#xD;
             such as active tuberculosis, unstable heart or liver disease, unstable diabetes,&#xD;
             symptomatic AIDS (non-symptomatic HIV infection is not an exclusion), or greater than&#xD;
             8 times the upper limit of normal in liver screening function tests (SGOT or SGPT)&#xD;
&#xD;
          -  Current neurological disorder (e.g., organic brain disease, dementia)&#xD;
&#xD;
          -  Major psychiatric disorder unrelated to substance abuse, such as schizophrenia or&#xD;
             bipolar disorder (assessed by the SCID and a medical history)&#xD;
&#xD;
          -  Suicide attempt within the month prior to enrollment and/or currently suicidal&#xD;
             (assessed by the SCID and the BDI II)&#xD;
&#xD;
          -  Currently on prescription medication that might interact with the study drug&#xD;
&#xD;
          -  Currently dependent on cocaine, opiates, alcohol, or benzodiazepines, as defined by&#xD;
             DSM-IV-TR criteria&#xD;
&#xD;
          -  History of alcohol dependence within past three years&#xD;
&#xD;
          -  History of seizure disorders&#xD;
&#xD;
          -  History of anorexia or bulimia&#xD;
&#xD;
          -  Current hypertension uncontrolled by medication&#xD;
&#xD;
          -  History of sensitivity to bupropion&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Shoptaw, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rancho Cucamonga Clinic</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <zip>91730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>August 23, 2005</study_first_submitted>
  <study_first_submitted_qc>August 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <name_title>Dr Steven Shoptaw</name_title>
    <organization>UCLA Department of Family Medicine</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

